Analyst Ratings For NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
Today, HC Wainwright initiated coverage on NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI) with a Buy with a price target of $25.00.
Some recent analyst ratings include
- 5/3/2018-HC Wainwright initiated coverage with a Buy rating.
- 4/2/2018-Canaccord Genuity initiated coverage with a Buy rating.
- 4/2/2018-BMO Capital Markets initiated coverage with a Outperform rating.
- 4/2/2018-UBS initiated coverage with a Buy rating.
- 4/2/2018-Barclays initiated coverage with a Overweight rating.
Recent Trading Activity for NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
Shares of NASDAQ:BTAI – BioXcel Therapeutics closed the previous trading session at 7.50 up +0.48 6.84% with 7.5 shares trading hands.